KSC · 068270.KS
Celltrion, Inc.
₩192,100+₩2,800 (+1.48%)
Celltrion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 19.76% below the high.
Loading market information…
KOE · 196170.KQ · KRW
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:22 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
Alteogen Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.45% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Alteogen Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of ₩968. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Alteogen Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:45 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| May 13, 2025 |
| ₩1,541-1.29% vs estimate |
| ₩83.7B+372.86% vs estimate |
| Q4 2024 | Mar 14, 2025 | ₩1,007 | ₩50.83B+24.58% vs estimate |
|---|
| Q3 2024 | Nov 13, 2024 | -₩175 | ₩6B0.0% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩192,100+₩2,800 (+1.48%)
Celltrion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 19.76% below the high.
HK$81.20-HK$0.40 (-0.49%)
Innovent Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.91% below the high.
$131.18+$1.15 (+0.88%)
Halozyme Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.03% below the high.
HK$433.40-HK$4.40 (-1.01%)
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 22.95% below the high.
HK$83.50HK$0.00 (0.0%)
Akeso, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.47% below the high.
CN¥95.29+CN¥1.67 (+1.78%)
RemeGen Co. Ltd. Class A’s quoted price sits in the lower half of its reported 52-week range, 39.61% below the high.
₩61,700-₩2,300 (-3.59%)
LigaChem Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.62% below the high.
₩39,000-₩2,000 (-4.88%)
ABL Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.82% below the high.
